-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

Benzinga·11/02/2026 20:48:06
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.